Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

805.23 -20.68 (-2.50%)
Official Closing Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Billionaire Philippe Laffont Just Sold Top Artificial Intelligence Stocks Nvidia and AMD and Piled Into 2 Players Dominating Another High-Growth Billion-Dollar Industry
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
How We Can Trade On GDP
What we got today, of course, was advance GPD, which is the earliest measure and also the most likely to provoke a reaction in stocks. 
Via Talk Markets
Topics Commodities Futures Stocks / Equities
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people. 
Via Benzinga
Topics Government
Exposures Political
Market Whales and Their Recent Bets on LLY Options
Via Benzinga
Assessing Eli Lilly: Insights From 7 Financial Analysts
Via Benzinga
Jim Cramer: This Industrial Stock Is 'Absolutely Terrific', First Solar Is 'Very Inexpensive'
First Solar will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on Tuesday, Feb. 25, 2025. 
Via Benzinga
Marjorie Taylor Greene Loads Up On Meta, Amazon, Tesla, Nvidia And Other Stocks As Donald Trump's New Equations With Big Tech Leaders Sets Stage For Growth: What Is At Stake?
U.S. House Representative Marjorie Taylor Greene has disclosed new trades as Donald Trump's equations evolves with Big Tech leaders. 
Via Benzinga
Topics Government
Exposures Political
What Does the Future Hold for Eli Lilly?
Eli Lilly's two major GLP-1 drugs have dominated headlines, but a slate of new treatments in development—and some already available—suggest a bright future. 
Via MarketBeat
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biotech And Healthcare Stocks Poised For Gains Ahead
The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech. 
Via Talk Markets
Topics ETFs Stocks / Equities
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.
Via The Motley Fool
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention. 
Via The Motley Fool
Prediction: 3 Stocks That'll Be Worth More Than Berkshire Hathaway 5 Years From Now
Even when it's performing well, Berkshire Hathaway can't outpace the market's very best growth prospects. 
Via The Motley Fool
Why Eli Lilly Stock Topped the Market Today
Via The Motley Fool
Friday's session: top gainers and losers in the S&P500 index
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
Novo Nordisk may have found a winner in amycretin. 
Via The Motley Fool
Allurion Catapults 200% On Its Plans To Outdo Eli Lilly, Novo Nordisk
While the other companies are testing weight-loss drugs, Allurion has a different approach to obesity. 
Via Investor's Business Daily
3 Richly Valued Stocks I'll Be Watching Like a Hawk in 2025
Via The Motley Fool
Novo Nordisk Stock Eyes Best Day In 17 Months On New Obesity Drug Trial Data: Retail Breathes Easy
The results also come as a relief following a selloff triggered by disappointing results from Novo’s CagriSema trial, which many deemed overblown. 
Via Stocktwits
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
The Danish drug giant reported a 22% weight loss over 36 weeks. 
Via Investor's Business Daily
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
Via The Motley Fool
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
Via The Motley Fool
Topics Earnings
Exposures Financial
My Top 5 Stocks to Buy in Early 2025
Via The Motley Fool
5 Stocks On Sale: Values Or Traps?
Lots of stocks can look cheap, especially after a sell-off. They may even have a low price-to-earnings (P/E) ratio. But that doesn’t mean the stock is a “value”. 
Via Talk Markets
Topics Stocks / Equities
Maxwell Biosciences Announces Appointment of José Antonio Alas to Its Board of Directors
Austin, Texas--(Newsfile Corp. - January 22, 2025) - Maxwell Biosciences ("Maxwell"), a pre-clinical drug platform company that develops Claromers™, ... 
Via Newsfile
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions 
Via MarketBeat
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end. 
Via Benzinga
Stock Of The Day: Lilly's Strong Support Level Signals Potential Rebound
Stock of the Day: Eli Lilly & Co. (LLY) is rebounding from Friday's sales disappointment, finding support at $722 and set for another uptrend. 
Via Benzinga
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS